^
    Back
    Association details:
    Biomarker:CLDN18.2 positive
    Cancer:Gastric Cancer
    Drug:AB011 (CLDN18.2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

    Excerpt:
    ...Tumor tissue samples is CLDN18.2 positive;...
    Trial ID:
    NCT04400383
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.

    Published date:
    01/17/2023
    Excerpt:
    Among 23 pts who had at least one tumor assessment by the data cut-off, 8/13 (61.5%) in 20mg/kg group and 7/10 (70%) in 30mg/kg group achieved PR. The ORR and DCR were 65.2% and 100% respectively….These results indicate that AB011, either in monotherapy or combined with chemotherapy, had a manageable safety profile and encouraging efficacy in CLDND18.2 positive advanced GC/GEJA and PC.
    Secondary therapy:
    CAPOX
    DOI:
    10.1200/JCO.2023.41.3_suppl.391
    Trial ID:
    NCT04400383